Digestive manifestations of SARS-COV2 infection in Togo

Digestive manifestations of SARS-COV2 infection in Togo

BAGNY Aklesso1,2, KOGOE Lidawu Roland-Moïse1*, LAWSON-ANANISSOH Laté Mawuli1,2, GBOLOU Mawunyo Henoc1, REDAH Debehoma Venceslas1, KANAKE Yendoukoa Yves1

1Gastroenterology and hepatology department of Campus teaching hospital, Lome, Togo; 2Gastroenterology and hepatology department; University of Lome, Togo.

Objective: to identify the main digestive manifestations related to SARS-CoV-2 in Togo and to determine their impact on the prognosis of the disease.

Patients and method: This was a cross-sectional study with retrospective and prospective collection, with descriptive and analytical aims, conducted from May 1, 2020 to April 30, 2021 at the national center for the management of infectious diseases of Lome. Patients of both sexes and of any age, tested positive for SARS-CoV-2 by PCR on nasopharyngeal and oropharyngeal samples and hospitalized at the national center for infectious disease management of Lome were included in this study. Digestive manifestations were divided into gastrointestinal manifestations and hepatobiliary manifestations. The threshold of significance of the tests was retained for a p value less than or equal to 0.05.

Results: out of 876 patients hospitalized during the study period, 215 presented with digestive manifestations, corresponding to a prevalence of 24.54%. the predominance was male, with a male/female sex ratio of 1.74. the mean age was 46.07+/-16.14 [02 months – 82 years]. gastrointestinal manifestations were found in 11.98% of cases. abdominal pain was the most frequent digestive symptom (15.35%). hepatobiliary manifestations were represented by cytolysis syndrome (44.19%) and cholestasis syndrome (36.28%). digestive manifestations were associated with renal failure (p=0.03) and thrombocytosis (p<0.01). The occurrence of death was associated with a decrease in HDL-cholesterol (p<0.001) and the presence of renal failure (p=0.027). The cure rate in our study was 83.72% with a lethality of 16.27%.

Conclusion: the digestive manifestations constitute a not negligible form of revelation of the disease with coronavirus 2019. The best prevention is the vaccination and the respect of the measures of social distanciation.

Keywords: digestive manifestations, COVID-19, SARS-COV 2, prognosis, death, Lome, Togo

Free Full-text PDF

How to cite this article:
BAGNY Aklesso, KOGOE Lidawu Roland-Moïse, LAWSON-ANANISSOH Laté Mawuli, GBOLOU Mawunyo Henoc, REDAH Debehoma Venceslas, KANAKE Yendoukoa Yves. Digestive manifestations of SARS-COV2 infection in Togo. Open Journal of Gastroenterology and Hepatology, 2022, 5:59. DOI: 10.28933/ojgh-2021-11-2205


1. Zhu N, Zhang D, Wang W, et al. A novel coro-navirus from patients with pneumonia in China, 2019. N Engl J Med.
2. Wu Y, Ho W, Huang Y, et al. SARS-CoV-2 is an appropriate name for the new coronavirus. The Lancet 2020; 395: 949–50.
3. Wong G, Liu W, Liu Y, et al. MERS, SARS, and Ebola: the role of super-spreaders in infectious disease. Cell Host Microbe 2015; 18: 398–401.
4. Hanen E, Mohamed G, Riadh B, Héla E. Mani-festations digestives de la Covid-19 ; Préva-lence et impact pronostique. In: La Tunisie Mé-dicale-2020, pp. 643–50.
5. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med.
6. Musa S. Hepatic and gastrointestinal in-volvement in coronavirus disease 2019 (CO-VID-19): What do we know till now? Arab J Gastroenterol 2020; 21: 3–8.
7. Characterisation WHOWGotC M of C. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020; 20: e192–7.
8. Ramachandran P, Onukogu I, Ghanta S, et al. Gastrointestinal symptoms and outcomes in hospitalized coronavirus disease 2019 patients. Dig Dis 2020; 38: 373–9.
9. Papa A, Covino M, Pizzolante F, et al. Gas-trointestinal symptoms and digestive comorbi-dities in an Italian cohort of patients with CO-VID-19. Eur Rev Med Pharmacol Sci 2020; 24: 7506–11.
10. Elmunzer BJ, Spitzer RL, Foster LD, et al. Di-gestive manifestations in patients hospitalized with coronavirus disease 2019. Clin Gastroen-terol Hepatol 2021; 19: 1355-65.
11. Nobel YR, Phipps M, Zucker J, et al. Gastroin-testinal symptoms and coronavirus disease 2019: a case-control study from the United States. Gastroenterology 2020; 159: 373.
12. Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection. J Biol Regul Homeost Agents 2020; 34: 339–43.
13. Chen R, Yu Y, Li W, et al. Gastrointestinal symptoms associated with unfavorable pro-gnosis of Covid-19 patients: A retrospective study. Front Med 2020; 7: 815.
14. Bonny V, Maillard A, Mousseaux C, et al. CO-VID-19: physiopathologie d’une maladie à plu-sieurs visages. Rev Médecine Interne 2020; 41: 375–89.
15. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial eco-logy and intestinal inflammation. Nature 2012; 487: 477–81.
16. Zhang H, Li H-B, Lyu J-R, et al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int J Infect Dis 2020; 96: 19–24.
17. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The lancet 2020; 395: 507–13.
18. Begue F, Tanaka S, Mouktadi Z, et al. Altered high-density lipoprotein composition and func-tions during severe COVID-19. Sci Rep 2021; 11: 1–16.

Terms of Use/Privacy Policy/ Disclaimer/ Other Policies:
You agree that by using our site, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies (click here for details)

CC BY 4.0
This work and its PDF file(s) are licensed under a Creative Commons Attribution 4.0 International License.